Menu
Fechar
hrs4r
 I want to donate

YOLANDA GONZALEZ MONTES

Haematology
Firma
YOLANDA GONZALEZ-MONTES
Position
Investigador/a Pre-doctoral – R1
Predoctoral Researchers – R1
Projectes
Publicacions

Projectes

Haematology

Ajuts per donar suport a les activitats dels grups de recerca de Catalunya (SGR-Cat 2021) - Hematologia

Codi oficial: 6822ZB3KJ Start date:01/01/2022 Data fi: 30/06/2025 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: AGÈNCIA DE GESTIÓ UNIVERSITARIS I RECERCA

Publicacions

Lakhwani S, Rosiñol L, Puig N, Pico-Picos MA, Medina-González L, Martínez-López J, Paiva B, Cedena MT, Oriol A, Ríos-Tamayo R, Blanchard MJ, Jarque I, Bargay J, Moraleda JM, Carrillo-Cruz E, Sureda A, Krsnik I, González E, Casado LF, Martí JM, Encinas C, De Arriba F, Palomera L, Sampol A, González-Montes Y, Motlló C, De La Cruz J, Alonso R, Mateos MV, Bladé J, Lahuerta JJ, San-Miguel J, Hernández MT

Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.

Haematologica, 2024, 109, 1909-1917 dx.doi.org/10.3324/haematol.2023.284154
González-Calle V, Rodríguez-Otero P, Sureda A, De Arriba F, Reinoso M, Ribas P, González-Rodríguez AP, González Y, Oriol A, Martínez-López J, González MS, Hernández MT, Sirvent M, Cedena T, Puig N, Paiva B, Bladé J, Lahuerta JJ, San-Miguel JF, Mateos MV

Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study.

Haematologica, 2024, 109, 2219-2228 dx.doi.org/10.3324/haematol.2023.284089
Gonzalez-Montes, Y, Osca-Gelis, G, Rodriguez-Romanos, R, Villavicencio, A, González-Bártulos, M, Llopis, F, Clapes, V, Oriol, A, Sureda, A, Escoda, L, Sarrà, J, Garzó, A, Lloveras, N, Gómez, B, Granada, I, Gallardo, D

CD200 genotype is associated with clinical outcome of patients with multiple myeloma

Frontiers in Immunology, 2024, 15 dx.doi.org/10.3389/fimmu.2024.1252445
Medina-Herrera, A, Vazquez, I, Cuenca, I, Rosa-Rosa, JM, Ariceta, B, Jimenez, C, Fernandez-Mercado, M, Larrayoz, MJ, Gutierrez, NC, Fernandez-Guijarro, M, Gonzalez-Calle, V, Rodriguez-Otero, P, Oriol, A, Rosiñol, L, Alegre, A, Escalante, F, De La Rubia, J, Teruel, AI, De Arriba, F, Hernandez, MT, Lopez-Jimenez, J, Ocio, EM, Puig, N, Paiva, B, Lahuerta, JJ, Bladé, J, San Miguel, JF, Mateos, MV, Martinez-Lopez, J, Calasanz, MJ, Garcia-Sanz, R, Rios, R, Sureda, A, Blanchard, MJ, Martinez-Martinez, R, Moraleda, JM, Bargay, J, Gironella, M, Palomera, L, Gonzalez-Montes, Y, Martí, JM, Krsnik, I, Arguiñano, JM, Gonzalez, ME, Gonzalez, AP, Casado, LF

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

BLOOD CANCER JOURNAL, 2024, 14 dx.doi.org/10.1038/s41408-024-01053-3
Alegre A, Gironella M, Escalante F, Bergua JM, Martínez-Chamorro C, López A, González E, Bárez A, Somolinos N, Persona EP, Cabrera AS, Soler A, Rodríguez BI, López JM, González Y, Giménez VC, Sampol A, Muñoz C, Vilanova D, Durán M, Fernández de Larrea C

Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real-world setting.

HemaSphere, 2024, 8 dx.doi.org/10.1002/hem3.81
Gonzalez-Montes Y, Rodriguez-Romanos R, Villavicencio A, Osca-Gelis G, González-Bártulos M, Llopis F, Clapes V, Oriol A, Sureda A, Escoda L, Sarrà J, Garzó A, Lloveras N, Díez I, Granada I, Gallardo D

Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma

Frontiers in Immunology, 2023, 14, 1158105-1158105 dx.doi.org/10.3389/fimmu.2023.1158105
Rosiñol L, Oriol A, Ríos-Tamayo R, Blanchard MJ, Jarque I, Bargay J, Hernandez Garcia MT, Cabañas V, Carrillo-Cruz E, Sureda A, Martinez-Lopez J, Krsnik I, Gonzalez ME, Casado Montero LF, Marti JM, Encinas C, de Arriba F, Palomera L, Sampol A, Gonzalez-Montes Y, Cabezudo E, Paiva B, Puig N, Cedena MT, de la Cruz J, Mateos MV, San-Miguel J, Lahuerta JJ, Bladé J

LENALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT IXAZOMIB MAINTENANCE TAILORED BY RESIDUAL DISEASE STATUS IN MYELOMA.

Blood, 2023, 142, 1518-1528 dx.doi.org/10.1182/blood.2022019531
Ocio EM, Montes-Gaisán C, Bustamante G, Garzón S, González E, Pérez-Persona E, González-Calle V, Sirvent M, Arguiñano JM, González Y, Ríos R, de Miguel D, Grande M, Fernández-Nistal A, Naves A, Rosiñol L

Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23, 341-347 dx.doi.org/10.1016/j.clml.2023.07.006
Dimopoulos MA, Schjesvold F, Doronin V, Vinogradova O, Quach H, Leleu X, Montes YG, Ramasamy K, Pompa A, Levin MD, Lee C, Mellqvist UH, Fenk R, Demarquette H, Sati H, Vorog A, Labotka R, Du J, Darif M, Kumar S

Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial

BLOOD CANCER JOURNAL, 2022, 12, 9-9 dx.doi.org/10.1038/s41408-021-00593-2
Ocio EM, Montes-Gaisán C, Bustamante G, Garzón S, González E, Pérez E, Sirvent M, Arguiñano JM, González Y, Ríos R, de Miguel D, Grande M, Fernández A, Naves A, Rosiñol L

Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22, 241-249 dx.doi.org/10.1016/j.clml.2021.10.001

Formulari de contacte

About IDIBGI!

 menu